CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says

MT Newswires Live

Oct 28

CSL's (ASX:CSL) flu revenue impact for the current Northern Hemisphere season is far worse than anticipated, driving the downgrade in the firm's revenue growth guidance, according to a Tuesday note by Jarden.

CSL cut its fiscal year 2026 revenue growth guidance to a range of 2% to 3% from its previous forecast of about 4% to 5%. The company also narrowed its net profit after tax and authorization growth outlook to a range of about 4% to 7% from its earlier guidance of about 7% to 10%.

The firm's Seqirus flu revenue is now expected to fall by "mid-teens" compared to a previous outlook of a decline of "high single digit". The Behring business appears to be performing in line with expectations.

The investment firm recommended an overweight rating on CSL and a price target of AU$304.17 per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578985192"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578985192\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578985192?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578985192","market":"fut","top_or_hot":-1,"title":"CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says","media":"MT Newswires Live","content":"<html><body><p> CSL's (ASX:CSL) flu revenue impact for the current Northern Hemisphere season is far worse than anticipated, driving the downgrade in the firm's revenue growth guidance, according to a Tuesday note by Jarden.</p><p>CSL cut its fiscal year 2026 revenue growth guidance to a range of 2% to 3% from its previous forecast of about 4% to 5%. The company also narrowed its net profit after tax and authorization growth outlook to a range of about 4% to 7% from its earlier guidance of about 7% to 10%.</p><p>The firm's Seqirus flu revenue is now expected to fall by \"mid-teens\" compared to a previous outlook of a decline of \"high single digit\". The Behring business appears to be performing in line with expectations.</p><p>The investment firm recommended an overweight rating on CSL and a price target of AU$304.17 per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-28 13:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL's (ASX:CSL) flu revenue impact for the current Northern Hemisphere season is far worse than anticipated, driving the downgrade in the firm's revenue growth guidance, according to a Tuesday note by Jarden.</p><p>CSL cut its fiscal year 2026 revenue growth guidance to a range of 2% to 3% from its previous forecast of about 4% to 5%. The company also narrowed its net profit after tax and authorization growth outlook to a range of about 4% to 7% from its earlier guidance of about 7% to 10%.</p><p>The firm's Seqirus flu revenue is now expected to fall by \"mid-teens\" compared to a previous outlook of a decline of \"high single digit\". The Behring business appears to be performing in line with expectations.</p><p>The investment firm recommended an overweight rating on CSL and a price target of AU$304.17 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2578985192","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578985192","pubTimestamp":1761630090,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL's  flu revenue impact for the current Northern Hemisphere season is far worse than anticipated, driving the downgrade in the firm's revenue growth guidance, according to a Tuesday note by Jarden.CSL cut its fiscal year 2026 revenue growth guidance to a range of 2% to 3% from its previous forecast of about 4% to 5%. The company also narrowed its net profit after tax and authorization growth outlook to a range of about 4% to 7% from its earlier guidance of about 7% to 10%.The firm's Seqirus flu revenue is now expected to fall by \"mid-teens\" compared to a previous outlook of a decline of \"high single digit\". The Behring business appears to be performing in line with expectations.The investment firm recommended an overweight rating on CSL and a price target of AU$304.17 per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"贾登表示，CSL对北半球赛季流感收入的影响导致指引下调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1.5,"CSL":1.5},"content_text":"CSL's (ASX:CSL) flu revenue impact for the current Northern Hemisphere season is far worse than anticipated, driving the downgrade in the firm's revenue growth guidance, according to a Tuesday note by Jarden.CSL cut its fiscal year 2026 revenue growth guidance to a range of 2% to 3% from its previous forecast of about 4% to 5%. The company also narrowed its net profit after tax and authorization growth outlook to a range of about 4% to 7% from its earlier guidance of about 7% to 10%.The firm's Seqirus flu revenue is now expected to fall by \"mid-teens\" compared to a previous outlook of a decline of \"high single digit\". The Behring business appears to be performing in line with expectations.The investment firm recommended an overweight rating on CSL and a price target of AU$304.17 per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}